In this review:
Funding
Rationale for use of tocilizumab in RA
Pharmacological properties of tocilizumab
Tocilizumab dosing forms and strengths
Clinical efficacy
Results from the Phase 4 ADACTA trial
ACT-RAY, ACT-STAR, ACT-SURE
Safety data
Tocilizumab shows good efficacy in sJIA
Please login below to download this issue (PDF)